eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model
Excerpt from the Press Release:
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) — eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration with the University of Miami Leonard M. Miller School of Medicine. The collaboration will encompass the evaluation of gene-edited pancreatic HuCo™ islet cells in a clinically relevant diabetes model as a prerequisite to advancing to human clinical trials. This collaboration is in addition to eGenesis’ existing partnerships with Massachusetts General Hospital, initiated in 2017, and Duke University School of Medicine, initiated in 2020.
The research of HuCo™ islet cell transplants will be conducted in the laboratory of Norma Sue Kenyon, Ph.D., Martin Kleiman Professor of Surgery, Microbiology & Immunology, Biomedical Engineering and Biochemistry & Molecular Biology at the Diabetes Research Institute, Miller School of Medicine.
“Advancements in gene editing technology have enabled the potential of developing and safely transplanting HuCo™ organs and cells into humans,” said Dr. Kenyon. “The goal is to develop an important medical advance for the 1.6 million Americans living with type 1 diabetes. Our research will evaluate genetically modified islet cells in a clinically relevant model of diabetes as a precursor to initiating human studies in the future if successful.”
Michael Curtis, Ph.D., President of Research & Development of eGenesis added, “Our mission is to develop HuCo™ organs and cells to improve the health and quality of life of all patients who could benefit from transplantation. This collaboration with the University of Miami has the potential to accelerate our research and provide additional validation of our HuCo™ islet cell program and may lead to their evaluation in human clinical trials in patients with type 1 diabetes. We look forward to working with Dr. Kenyon and her colleagues to advance the field of organ and cell transplantation.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?